In vivo production of small interfering RNAs that mediate gene silencing
The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells.
1. An isolated nucleic acid molecule comprising a regulatory sequence operably linked to a nucleic acid sequence that encodes an engineered ribonucleic acid (RNA) precursor which is processed to form a small interfering ribonucleic acid (siRNA) comprising an antisense strand complementary to a sequence of a messenger RNA (mRNA) of a target gene, and a sense strand having a sequence complementary to the antisense strand, wherein the engineered RNA precursor comprises:
(i) a first stem portion of the engineered RNA precursor comprising a sequence of at least 18 nucleotides that is complementary to a sequence of the mRNA;
(ii) a second stem portion of the engineered RNA precursor comprising a sequence of at least 18 nucleotides that is sufficiently complementary to the first stem portion to hybridize with the first stem portion to form a duplex; and
(iii) a loop portion of the engineered RNA precursor consisting of 2 to 9 nucleotides that connects said first and said second stem portions.
2. The nucleic acid molecule of claim 1 , wherein the target sequence of the mRNA is located from 100 to 300 nucleotides 3′ of the start of translation of the mRNA, or is located in a 5′ untranslated region (UTR) or a 3′ UTR of the mRNA.
3. The nucleic acid molecule of claim 1 , wherein one or more of:
the first and second stem portions each comprise about 22 to about 28 nucleotides,
the first and second stem portions each comprise the same number of nucleotides; and
one of the first and second stem portions comprises 1 to 4 more nucleotides than the other stem portion.
4. The nucleic acid molecule of claim 1 , wherein the regulatory sequence comprises a Pol III or Pol II promoter and said promoter is optionally constitutive.
5. The nucleic acid molecule of claim 1 , wherein the sequence of the engineered RNA precursor is the sequence set forth in SEQ ID NO: 2, 3, 4, 5, 8, 9, 10, 11, 17, 18, 20, or 21, or a complement thereof.
6. The isolated nucleic acid molecule of claim 1 , wherein the first stem portion is fully complementary to the mRNA sequence.
7. The isolated nucleic acid molecule of claim 1 , wherein the second stem portion is fully complementary to the first stem portion.
8. The isolated nucleic acid molecule of claim 1 , wherein the first stem portion is located at a 5′ end of the RNA precursor.
9. The isolated nucleic acid molecule of claim 1 , wherein the first stem portion is located at a 3′ end of the RNA precursor.
10. A vector comprising the nucleic acid molecule of claim 1 .
11. The vector of claim 10 , wherein the vector is a plasmid or a viral vector.
12. The vector of claim 11 , wherein the viral vector is a retroviral vector.
13. An isolated host cell containing the nucleic acid molecule of claim 1 .
14. The host cell of claim 13 , wherein the cell is a mammalian cell.
15. A transgene comprising the nucleic acid of claim 1 .
16. An engineered RNA precursor which is processed to form an siRNA comprising an antisense strand complementary to a sequence of an mRNA of a target gene, and a sense strand having a sequence complementary to the antisense strand, wherein the engineered RNA precursor comprises:
(i) a first stem portion of the engineered RNA precursor comprising a sequence of at least 18 nucleotides that is complementary to a portion of the mRNA;
(ii) a second stem portion of the engineered RNA precursor comprising a sequence of at least 18 nucleotides that is sufficiently complementary to the first stem portion to hybridize with the first stem portion to form a duplex stem; and
(iii) a loop portion of the engineered RNA precursor consisting of 2 to 9 nucleotides that connects the two stem portions.
17. The engineered RNA precursor of claim 16 , wherein the sequence of the mRNA is located in a 5′ untranslated region (UTR) or a 3′ UTR of the mRNA.
18. The precursor of claim 16 , comprising the sequence set forth in SEQ ID NO: 2, 3, 4, 5, 8, or 9.
19. The precursor of claim 16 , wherein the target gene is a wild-type or mutant human gene or viral gene.
20. The engineered RNA precursor of claim 16 , wherein the first stem portion is fully complementary to the mRNA sequence.
21. The engineered RNA precursor of claim 16 , wherein the second stem portion is fully complementary to the first stem portion.
22. The engineered RNA precursor of claim 16 , wherein the first stem portion is located at a 5′ end of the RNA precursor.
23. The engineered RNA precursor of claim 16 , wherein the first stem portion is located at a 3′ end of the RNA precursor.
24. The engineered RNA precursor of claim 16 , wherein the first and second stem portions each comprise the same number of nucleotides.
25. The engineered RNA precursor of claim 16 , wherein one of the first and second stem portions comprises 1 to 4 more nucleotides than the other stem portion.
26. A transgenic, non-human animal expressing a transgene comprising a nucleic acid molecule of claim 1 , wherein the transgene is expressed in one or more cells of the transgenic animal resulting in the animal exhibiting ribonucleic acid interference (RNAi) of the target gene by the engineered RNA precursor.
27. The transgenic animal of claim 26 , wherein the animal is a mouse.
28. The transgenic, non-human animal of claim 26 , wherein the transgene is expressed in one or any combination of cardiac cells, lymphocytes, liver cells, vascular endothelial cells and spleen cells.
29. The transgenic, non-human animal of claim 26 , wherein the regulatory sequence is constitutive or inducible.
30. The transgenic, non-human animal of claim 26 , wherein the regulatory sequence is tissue specific.
31. The transgenic, non-human animal of claim 26 , wherein the regulatory sequence is a Pol III or Pol II promoter.
32. The transgenic, non-human animal of claim 26 , wherein the regulatory sequence is an exogenous sequence.
33. The transgenic, non-human animal of claim 26 , wherein the animal is a non-human primate or rodent.
34. A cell derived from the transgenic animal of claim 26 , wherein said cell is selected from the group consisting of a lymphocyte, a liver cell, a cardiac cell, a vascular endothelial cell, and a spleen cell.
35. A method of inducing ribonucleic acid interference (RNAi) of a target gene in a cell in an animal, the method comprising
obtaining a transgenic animal of claim 26 comprising a transgene comprising a nucleic acid molecule encoding an engineered RNA precursor and an inducible promoter; and
inducing the cell to express the precursor to form a small interfering ribonucleic acid (siRNA) within the cell, thereby inducing RNAi of the target gene in the animal.
36. A method of inducing ribonucleic acid interference (RNAi) of a target gene in a cell, the method comprising
obtaining a host cell of claim 13 ;
culturing the cell; and
enabling the cell to express the RNA precursor to form a small interfering ribonucleic acid (siRNA) within the cell, thereby inducing RNAi of the target gene in the cell.